Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep;38(9):2023-2026.
doi: 10.1038/s41375-024-02329-0. Epub 2024 Jul 5.

Integration of genetics and MRD to define low risk patients with B-cell precursor acute lymphoblastic leukaemia with intermediate MRD levels at the end of induction

Anthony V Moorman  1 , Amir Enshaei  2 , Daniel Murdy  2 , Melvin Joy  2 , Judith M Boer  3 , Monique L den Boer  3 , Rob Pieters  3 , Valerie de Haas  3 , Martin A Horstmann  4 , Gabriele Escherich  4 , Bertil Johansson  5   6 , Hanne V Marquart  7   8 , Kjeld Schmiegelow  8   9 , Jeremy Hancock  10 , John Moppett  11 , Mats Heyman  12
Affiliations

Integration of genetics and MRD to define low risk patients with B-cell precursor acute lymphoblastic leukaemia with intermediate MRD levels at the end of induction

Anthony V Moorman et al. Leukemia. 2024 Sep.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Outcome of patients classified as Intermediate Risk (IR) low and high according to genetics and end of induction MRD levels.
A–C Kaplan-Meier plots illustrating the improved outcome for patients classified into the IR-low subgroup; D Forest plots showing the hazard ratios for EFS, RR, OS comparing IR-high against IR-low by NCI risk group and study group.
See this image and copyright information in PMC

References

    1. Pieters R, de Groot-Kruseman H, Van der Velden V, Fiocco M, van den Berg H, de Bont E, et al. Successful therapy reduction and intensification for childhood acute lymphoblastic leukemia based on minimal residual disease monitoring: study ALL10 from the Dutch Childhood Oncology Group. J Clin Oncol. 2016;34:2591–601. 10.1200/JCO.2015.64.6364 - DOI - PubMed
    1. O’Connor D, Enshaei A, Bartram J, Hancock J, Harrison CJ, Hough R, et al. Genotype-specific minimal residual disease interpretation improves stratification in pediatric acute lymphoblastic leukemia. J Clin Oncol. 2018;36:34–43. 10.1200/JCO.2017.74.0449 - DOI - PMC - PubMed
    1. O’Connor D, Moorman AV, Wade R, Hancock J, Tan RM, Bartram J, et al. Use of Minimal Residual Disease Assessment to Redefine Induction Failure in Pediatric Acute Lymphoblastic Leukemia. J Clin Oncol. 2017;35:660–7. 10.1200/JCO.2016.69.6278 - DOI - PubMed
    1. Toft N, Birgens H, Abrahamsson J, Griskevicius L, Hallbook H, Heyman M, et al. Results of NOPHO ALL2008 treatment for patients aged 1–45 years with acute lymphoblastic leukemia. Leukemia 2018;32:606–15 - PubMed
    1. Buchmann S, Schrappe M, Baruchel A, Biondi A, Borowitz M, Campbell M, et al. Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium. Blood. 2022;139:1785–93. 10.1182/blood.2021012328 - DOI - PMC - PubMed

LinkOut - more resources